Guinea-BissauTuberculosis profile
Population  2017 1.9 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.4 (0.83–2.2) 77 (44–118)
Mortality (HIV+TB only) 1.2 (0.75–1.8) 66 (40–99)
Incidence  (includes HIV+TB) 7 (4.5–9.9) 374 (242–534)
Incidence (HIV+TB only) 2.2 (1.4–3.2) 119 (75–174)
Incidence (MDR/RR-TB)** 0.19 (0.075–0.36) 10 (4–19)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.44 (0.4–0.48) 2.2 (1.7–2.7) 2.7 (2–3.3)
Males 0.49 (0.44–0.54) 3.8 (2.7–4.9) 4.3 (3–5.6)
Total 0.93 (0.79–1.1) 6 (3.8–8.2) 7 (4.5–9.9)
TB case notifications, 2017  
Total cases notified 2 248
Total new and relapse 2 226
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 75%
          - % pulmonary 95%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 32% (22–49)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.4 (0.21–0.6)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 528 31%
          - on antiretroviral therapy 235 45%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  58
(24–91)
Estimated % of TB cases with MDR/RR-TB 2.5% (1.1–4.3) 14% (10–18)  
% notified tested for rifampicin resistance <1% 44% 31
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 31, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 25, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 76% 2 226
Previously treated cases, excluding relapse, registered in 2016 43% 21
HIV-positive TB cases registered in 2016 73% 506
MDR/RR-TB cases started on second-line treatment in 2015 47% 15
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
19% (18–21)
TB financing, 2018  
National TB budget (US$ millions) 2.8
Funding source: 11% domestic, 64% international, 25% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-11-21 Data: www.who.int/tb/data